Familial hyperaldosteronism type I

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

4 events
Jan 2026Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

IRCCS Centro Neurolesi Bonino Pulejo — NA

TrialRECRUITING
Jun 2024First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP

Sumitomo Pharma Co., Ltd. — PHASE1

TrialACTIVE NOT RECRUITING
Dec 2023Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Fred Hutchinson Cancer Center — PHASE1

TrialRECRUITING
Jul 2021Effects of GRA in Patients With Type 1

University of California, San Diego — PHASE2

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Familial hyperaldosteronism type I.
Check the disease page for updates →

Clinical Trial Landscape

No active clinical trials currently recruiting for Familial hyperaldosteronism type I.
Search all trials →
Search clinical trials for Familial hyperaldosteronism type I

Recent News & Research

No recent news articles indexed yet for Familial hyperaldosteronism type I.
Search PubMed for Familial hyperaldosteronism type I

Browse all Familial hyperaldosteronism type I news →

Specialist Network

Top 2 by expertise

View all Familial hyperaldosteronism type I specialists →

Quick Actions